کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5844141 | 1127558 | 2011 | 20 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
DihydroergotamineEDHFGTNN-methyl d-aspartateRAMP1VPMi.v.PACAPCSD5-HTnNOSNMDACGRPAMPA5-hydroxytryptamineeNOSMCASSSiNOSCGRP receptor antagonistsReceptor activity modifying protein 1NOSVIPl-NAME - L-NAMENω-nitro-l-arginine methyl ester (L-NAME) - N-NITRO-L-آرژینین متیل استر (L-NAME)α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid - اسید α-آمینو 3-هیدروکسی-5-متیل-4-ایزوکسول پپونیکcortical spreading depression - افسردگی گسترش کورتکسCNS - دستگاه عصبی مرکزیinducible nitric oxide synthase - سنتاز اکسید نیتریک القاییendothelial nitric oxide synthase - سنتاز اکسید نیتریک اندوتلیالneuronal nitric oxide synthase - سنتاز اکسید نیتریک عصبیcentral nervous system - سیستم عصبی مرکزیsuperior sagittal sinus - سینوسی سرایتتال برترmiddle cerebral artery - شریان مغزی میانیEndothelium-derived hyperpolarizing factor - فاکتور هیپرپولاریزاسیون حاصل از اندوتلیومMigraine - میگرنNeuropeptides - نوروپپتیدهاNitric oxide - نیتریک اکسیدnitric oxide synthase - نیتریک اکسید سنتازDHE - وpituitary adenylate cyclase activating polypeptide - پلی پپتید فعال کننده adenylate cyclase فعال در هیپوفیزvasoactive intestinal peptide - پپتید روده روده ایcalcitonin gene-related peptide - پپتید مرتبط با ژن کلسی تونینPACAP receptor - گیرنده PACAP
موضوعات مرتبط
علوم پزشکی و سلامت
داروسازی، سم شناسی و علوم دارویی
داروشناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Currently available drugs for the acute treatment of migraine, i.e. ergot alkaloids and triptans, are cranial vasoconstrictors. Although cranial vasoconstriction is likely to mediate-at least a part of-their therapeutic effects, this property also causes vascular side-effects. Indeed, the ergot alkaloids and the triptans have been reported to induce myocardial ischemia and stroke, albeit in extremely rare cases, and are contraindicated in patients with known cardiovascular risk factors. In view of these limitations, novel antimigraine drugs devoid of vascular (side) effects are being explored. Currently, calcitonin gene-related peptide (CGRP) receptor antagonists, which do not have direct vasoconstrictor effects, are under clinical development. Other classes of drugs, such as 5-HT1F receptor agonists, glutamate receptor antagonists, nitric oxide synthase inhibitors, VPAC/PAC receptor antagonists and gap junction modulators, have also been proposed as potential targets for acute antimigraine drugs. Although these prospective drugs do not directly induce vasoconstriction, they may well induce indirect vascular effects by inhibiting or otherwise modulating the responses to endogenous vasoactive substances. These indirect vascular effects might contribute to the therapeutic efficacy of the previously mentioned compounds, but may alternatively also lead to vascular side-effects. As described in the current review, some of the prospective antimigraine drugs with a proposed non-vascular mechanism of action may still have direct or indirect vascular effects.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Pharmacology & Therapeutics - Volume 129, Issue 3, March 2011, Pages 332-351
Journal: Pharmacology & Therapeutics - Volume 129, Issue 3, March 2011, Pages 332-351
نویسندگان
Kayi Y. Chan, Steve Vermeersch, Jan de Hoon, Carlos M. Villalón, Antoinette MaassenVanDenBrink,